Market Indices
Latest News
| ||
| ||
Price Targets
from Lake Street issued a price target of $32.00 for KZIA on 2026-06-11 11:40:16.The adjusted price target was set to $32.00.At the time of the announcement, KZIA...
June 11, 2026 KZIA 13.88%
from Wedbush issued a price target of $100.00 for NICE on 2026-06-10 12:51:46.The adjusted price target was set to $100.00.At the time of the announcement, NICE was...
June 10, 2026 NICE 0.72%
Market Movers
| Top Gainers (%) | |||||||||||||||||||
| YI 111, Inc. | 4.89
14.25% | ||||||||||||||||||
| KZIA Kazia Therapeutics Limite | 14.28
13.88% | ||||||||||||||||||
| MOLN Molecular Partners AG | 4.11
10.78% | ||||||||||||||||||
| SMMT Summit Therapeutics Inc. | 14.01
7.11% | ||||||||||||||||||
| JKS JinkoSolar Holding Co., L | 19.71
6.20% | ||||||||||||||||||
| WDS Woodside Energy Group Ltd | 23.07
6.17% | ||||||||||||||||||
| CMPS COMPASS Pathways plc | 12.08
5.87% | ||||||||||||||||||
| DBVT DBV Technologies S.A. | 17.42
5.29% | ||||||||||||||||||
Annual/Quarterly Reports Summary
Summit Therapeutics Inc. (SMMT) Quarterly Report: What Does It Reveal About Their Sector Performance
May 1, 2025 SMMT 7.11%
In a landscape of rising revenues and increasing operational costs, the company navigates challenges with a focus on innovation and sustainability. Despite a dip in net income and profit declines...
February 5, 2025 TEVA 0.20%
In a year marked by resilience, the company celebrated record revenues of $25 billion, driven by strong ticket sales and operational efficiency. With a focus on North America, it reduced...
January 27, 2025 TEVA 0.20%